HRP20171836T1 - Polukruti vodeni farmaceutski pripravak koji sadrži tapentadol - Google Patents

Polukruti vodeni farmaceutski pripravak koji sadrži tapentadol Download PDF

Info

Publication number
HRP20171836T1
HRP20171836T1 HRP20171836TT HRP20171836T HRP20171836T1 HR P20171836 T1 HRP20171836 T1 HR P20171836T1 HR P20171836T T HRP20171836T T HR P20171836TT HR P20171836 T HRP20171836 T HR P20171836T HR P20171836 T1 HRP20171836 T1 HR P20171836T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical preparation
preparation according
tapentadol
pharmaceutical
preservative
Prior art date
Application number
HRP20171836TT
Other languages
English (en)
Croatian (hr)
Inventor
Ulrich Reinhold
Marc Schiller
Eva WULSTEN
Sabine Karine Katrien Inghelbrecht
Roger Carolus Augusta Embrechts
Ulrich Feil
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of HRP20171836T1 publication Critical patent/HRP20171836T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HRP20171836TT 2011-03-04 2012-03-02 Polukruti vodeni farmaceutski pripravak koji sadrži tapentadol HRP20171836T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161449329P 2011-03-04 2011-03-04
EP11003603 2011-05-03
EP12710026.1A EP2680834B1 (en) 2011-03-04 2012-03-02 Semisolid aqueous pharmaceutical composition containing tapentadol
PCT/EP2012/000906 WO2012119729A1 (en) 2011-03-04 2012-03-02 Semisolid aqueous pharmaceutical composition containing tapentadol

Publications (1)

Publication Number Publication Date
HRP20171836T1 true HRP20171836T1 (hr) 2017-12-29

Family

ID=44652117

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171836TT HRP20171836T1 (hr) 2011-03-04 2012-03-02 Polukruti vodeni farmaceutski pripravak koji sadrži tapentadol

Country Status (24)

Country Link
US (3) US9446008B2 (enExample)
EP (3) EP3766489B1 (enExample)
JP (3) JP6027549B2 (enExample)
KR (2) KR102039320B1 (enExample)
CN (1) CN103501774A (enExample)
AU (2) AU2012224954C1 (enExample)
BR (1) BR112013022556A8 (enExample)
CA (1) CA2828637C (enExample)
CY (1) CY1119725T1 (enExample)
DK (1) DK2680834T3 (enExample)
EA (2) EA025194B1 (enExample)
ES (2) ES2910085T3 (enExample)
HR (1) HRP20171836T1 (enExample)
HU (1) HUE037491T2 (enExample)
IL (2) IL227826B (enExample)
LT (1) LT2680834T (enExample)
MX (2) MX374468B (enExample)
NO (1) NO2680834T3 (enExample)
PL (1) PL2680834T3 (enExample)
PT (2) PT3766489T (enExample)
RS (1) RS56692B1 (enExample)
SI (1) SI2680834T1 (enExample)
WO (1) WO2012119729A1 (enExample)
ZA (1) ZA201306480B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103501773A (zh) 2011-03-04 2014-01-08 格吕伦塔尔有限公司 用于口服给予的他喷他多含水药物制剂
NO2680834T3 (enExample) 2011-05-03 2018-03-17
US9395306B2 (en) 2011-08-05 2016-07-19 Halliburton Energy Services, Inc. Methods for monitoring fluids within or produced from a subterranean formation during acidizing operations using opticoanalytical devices
US8997860B2 (en) 2011-08-05 2015-04-07 Halliburton Energy Services, Inc. Methods for monitoring the formation and transport of a fracturing fluid using opticoanalytical devices
US8619256B1 (en) 2012-09-14 2013-12-31 Halliburton Energy Services, Inc. Systems and methods for monitoring the properties of a fluid cement composition in a flow path
US20140076550A1 (en) 2012-09-14 2014-03-20 Halliburton Energy Services, Inc. Systems and Methods for Detecting Microannulus Formation and Remediation
US9228940B2 (en) 2012-09-14 2016-01-05 Halliburton Energy Services, Inc. Systems, methods, and apparatuses for in situ monitoring of cement fluid compositions and setting processes thereof
WO2015014980A1 (en) * 2013-08-02 2015-02-05 Ratiopharm Gmbh Composition comprising tapentadol in a dissolved form
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
ES2710299T3 (es) 2015-03-27 2019-04-24 Gruenenthal Gmbh Formulación estable para la administración parenteral de tapentadol
ES3027562T3 (en) * 2016-09-23 2025-06-16 Gruenenthal Gmbh Stable formulation for parenteral administration of tapentadol
EP3826631A1 (en) * 2018-07-24 2021-06-02 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical emulsion of an anticholinergic compound
MX2021011355A (es) 2019-03-18 2021-10-13 Sunstar Americas Inc Composicion para cuidado oral.

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775678A (en) * 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6183758B1 (en) * 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
PL223471B1 (pl) 2002-03-15 2016-10-31 Cypress Bioscience Inc Kompozycja farmaceutyczna zawierająca milnacypran do stosowania w leczeniu zespołu nadwrażliwości jelita grubego
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
WO2004024126A1 (en) 2002-09-13 2004-03-25 Cydex, Inc. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
WO2005112926A1 (en) 2004-05-17 2005-12-01 Pharmacofore, Inc. Compositions and methods for treating or preventing pain
DE602004007905T2 (de) 2004-06-28 2008-05-08 Grünenthal GmbH Kristalline Formen von (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
JP5700904B2 (ja) 2004-07-01 2015-04-15 グリューネンタール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング (1r,2r)−3−(3−ジメチルアミノ−1−エチル−2−メチル−プロピル)フェノールを含有する乱用防止経口投与形態物
CA2606947A1 (en) 2005-04-28 2006-11-02 Theraquest Biosciences Llc Methods and compositions for treating pain
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
US20080039405A1 (en) * 2006-04-25 2008-02-14 Croda, Inc. Modification of percutaneous absorption of topically active materials
EP2012764B1 (en) 2006-04-28 2011-01-12 Grünenthal GmbH Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol
PT2012763E (pt) 2006-04-28 2011-04-29 Gruenenthal Gmbh Combinação farmacêutica que compreende 3-(3-dimetilamino-1-etil-2-metil-propil)fenol e um aine
CA2656696C (en) 2006-07-24 2013-06-11 Janssen Pharmaceutica N.V. Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
KR101607112B1 (ko) * 2007-11-23 2016-03-29 그뤼넨탈 게엠베하 타펜타돌 조성물
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
ES2758831T3 (es) * 2008-10-30 2020-05-06 Gruenenthal Gmbh Nuevas y potentes formas de dosificación de tapentadol
US20100227921A1 (en) 2009-03-03 2010-09-09 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
US20100272815A1 (en) 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
US20110190267A1 (en) * 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
EP2552486B1 (en) * 2010-03-30 2020-08-12 Phosphagenics Limited Transdermal delivery patch
GB201006200D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
US20120270848A1 (en) * 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
NO2680834T3 (enExample) 2011-05-03 2018-03-17

Also Published As

Publication number Publication date
AU2012224954B2 (en) 2016-10-20
HUE037491T2 (hu) 2018-09-28
JP2014506900A (ja) 2014-03-20
CA2828637C (en) 2019-06-11
KR102039320B1 (ko) 2019-11-01
JP6259042B2 (ja) 2018-01-10
AU2012224954C1 (en) 2017-04-06
EA025194B1 (ru) 2016-11-30
PT3766489T (pt) 2022-04-07
BR112013022556A2 (pt) 2016-12-06
AU2017200040B2 (en) 2018-09-06
US20120225950A1 (en) 2012-09-06
MX374468B (es) 2025-03-06
EA201300988A1 (ru) 2014-06-30
JP2018065839A (ja) 2018-04-26
RS56692B1 (sr) 2018-03-30
CA2828637A1 (en) 2012-09-13
AU2012224954A1 (en) 2013-09-19
EA033171B1 (ru) 2019-09-30
WO2012119729A1 (en) 2012-09-13
EP2680834B1 (en) 2017-10-18
EP2680834A1 (en) 2014-01-08
AU2017200040A1 (en) 2017-02-02
KR101911362B1 (ko) 2018-10-25
BR112013022556A8 (pt) 2018-01-16
JP2017039756A (ja) 2017-02-23
PT2680834T (pt) 2018-01-25
DK2680834T3 (en) 2017-12-04
KR20180116463A (ko) 2018-10-24
SI2680834T1 (en) 2018-01-31
CY1119725T1 (el) 2018-06-27
ES2910085T3 (es) 2022-05-11
CN103501774A (zh) 2014-01-08
IL227826B (en) 2018-04-30
EP3290029A1 (en) 2018-03-07
ZA201306480B (en) 2014-05-28
MX344473B (es) 2016-12-16
IL258357A (en) 2018-05-31
EA201600442A1 (ru) 2017-02-28
US9446008B2 (en) 2016-09-20
IL227826A0 (en) 2013-09-30
KR20140013020A (ko) 2014-02-04
NO2680834T3 (enExample) 2018-03-17
MX2013010100A (es) 2013-10-01
US20160346229A1 (en) 2016-12-01
ES2654407T3 (es) 2018-02-13
JP6027549B2 (ja) 2016-11-16
PL2680834T3 (pl) 2018-03-30
LT2680834T (lt) 2018-01-10
US20180133174A1 (en) 2018-05-17
JP6670283B2 (ja) 2020-03-18
EP3766489B1 (en) 2022-03-16
EP3290029B1 (en) 2020-09-02
EP3766489A1 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
HRP20171836T1 (hr) Polukruti vodeni farmaceutski pripravak koji sadrži tapentadol
BR112014010275A2 (pt) formulações para tratamento de diabetes
JP6794420B2 (ja) 外用医薬組成物
HRP20210085T1 (hr) Pripravci i postupci za liječenje disfunkcije meibomske žlijezde
BR112014029766A2 (pt) composições contendo álcoois graxos, tensoativos catiônicos e n-acil-n-metilglucaminas
HRP20200513T1 (hr) Topikalni pripravci koji sadrže fipronil i permetrin te postupci njihove uporabe
EP2275104A3 (en) Pharmaceutical and cosmetic composition including lactoferrin, ciclopirox and etidronic acid
JP2014517028A5 (enExample)
HRP20230726T1 (hr) Topikalna formulacija za poticanje zarastanja rana
Tou et al. Influence of omega fatty acids on skin permeation of a coenzyme Q10 nanoemulsion cream formulation: characterization, in silico and ex vivo determination
JP7664689B2 (ja) 外用組成物
RU2017109903A (ru) Композиции диклофенака натрия для местного применения
RU2018111036A (ru) Композиции, содержащие экстракт эхинацеи и производные соединения линолевой кислоты
JP2015512926A5 (enExample)
WO2007146816A3 (en) Tamanu oil products
HRP20191059T1 (hr) Skup aktivnih sastojaka za topikalnu primjenu u restrukturiranju izmijenjene kožne barijere poslije kožnih bolesti
EA201291335A1 (ru) Фармацевтические композиции для местного применения
AR087488A1 (es) Uso de composiciones para retrasar el inicio de la fase catagena del cabello
AR089197A1 (es) Composiciones cosmeticas de aceite en agua
ES2541379B1 (es) Cosmética natural de bellota
SI2874614T1 (en) Water-soluble film which has a healing effect
AR102132A1 (es) Composición cosmética y/o farmacéutica en forma de dispersión, procedimiento de preparación y utilización para el tratamiento de la piel
CN107126391A (zh) 一种抗炎修复组合物及其应用
HRP20210266T1 (hr) Pripravak prikladan za očuvanje fiziološkog stanja kože i kose i ponovnu uspostavu njihovih regenerativnih funkcija
ES2362066B1 (es) Preparación combinada para el tratamiento de la psoriasis.